Nephrotoxicity of intravenous immunoglobulins in the setting of liver transplantation for HBV-related cirrhosis: An undervalued topic?;Nefrotossicità delle immunoglobuline endovenose nel trapianto di fegato per cirrosi HBV-correlata: Un argomento sottovalutato?

Minerva Gastroenterologica e Dietologica

Volumn 54, Issue 3, 2008, Pages 259-275

  Angeli, P ^a   Scaglione, F ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Hepatitis B virus; Immunglobulins, intravenous; Liver transplantation

Indexed keywords

ADEFOVIR DIPIVOXIL; CALCINEURIN INHIBITOR; CYCLOSPORIN A; IMMUNOGLOBULIN; LAMIVUDINE; IMMUNOLOGIC FACTOR;

ANTIVIRAL THERAPY; BACKACHE; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DIALYSIS; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HEPATITIS B; HUMAN; INFECTION PREVENTION; KIDNEY DISEASE; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LOW DRUG DOSE; MONOTHERAPY; NEPHROSIS; NEPHROTOXICITY; NONHUMAN; OLIGURIA; OUTCOME ASSESSMENT; PATHOGENESIS; PRACTICE GUIDELINE; RECOMMENDED DRUG DOSE; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SKIN TINGLING; TREATMENT INDICATION; TREATMENT OUTCOME; VIRUS LOAD; ACUTE KIDNEY FAILURE; CHEMICALLY INDUCED DISORDER; CHRONIC KIDNEY FAILURE; EVIDENCE BASED MEDICINE; VIROLOGY;

EVIDENCE-BASED MEDICINE; HEPATITIS B; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; KIDNEY FAILURE; KIDNEY FAILURE, ACUTE; KIDNEY FAILURE, CHRONIC; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PRACTICE GUIDELINES AS TOPIC;

EID: 57449101899     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. National Institutes of Health. Intravenous Immunoglnhulin Prevention and Treatment Of Diseases. Consensus Development Conference statement. [May 21-23 1990; cited June 2000]. Available at: http://concensus.nih.gov/1990/ 1990IntravenousImmunoglobulin080html.htm
2. Winward DB, Brophy MT. Acute renal failure after administration of intravenous immunoglohulin therapy. Pharmacotherapy 1995;16:765-72.
3. Ahsan M, Wiegand LA, Abendroth CS, Manning EC. Acute renal failure following immunoglobulin therapy. Am J Nephrol 1996;16:532-6.
4. Chako B, John GT, Balakrishanan N, Kirubankaran MG, Chakko KB. Osmotic nephropathy from maltose-based intravenous immunoglobulin therapy. Renal failure 2006;28:193-5.
5. Renal insufficiency and failure associated with immune globulin intravenous therapy; United States, 1985-1988. MMWR Morb Mortal Wkly Rep 1999;48:518-21.
6. Brannagan TH, Nagle KJ, Lange DJ, Rowland LP. Complications of intravenous immune globulin treatment in neurologic disease. Neurology 1996;47:674-7.
7. Schiavotto C, Ruggeri M, Rodeghiero F. Adversereactions after high dose intravenous immunoglobulin: incidence in 83 patients treated for idiophatic thrombocytopenia (ITP, and review of the literature. Haematologica 1993;78(Suppl. 2.:35-40.
8. Tan E, Hjinazarian M, Bay W, Neff J, Mendell JR. Acute renal failure resulting from IVIG therapy. Arch Neurol 1993; 50:137-9.
9. Pasatiempo AM, Kroser JA, Rudnick M, Hoffman BI. Acute renal failure after intravenous immunoglobulintherapy. J Rheumatol 1994;21:347-9.
10. Laidlow S, Bainton R, Wilkie M, Makris M. Acute renal failure in acquired haemophilia following the use of hight dose intravenous immunoglubulin. Haemophilia 1999;5:270-2.
11. McRogers R. Not all intravenous immunoglobulins are the same:approriate selection in patients with compromised renal function. Pharmacotherapy 2006;26:296-7.
12. Lemm H. Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy. Neurology 2002;59 (12 Suppl. 6.:s28-s32.
13. Chapman SA, Gilkerson KL, Dawin TD, Pritzkner MR. Acute renal failure and intravenous immune globulin: occurs with sucrose-stabilized, but not with D-sorbitol-stabilized, formulation. Ann Pharmacother 2004;38:2059-67.
14. Van Zanten AR, Beekhuyzenn M, Van Deer Mer YG, De Gooijer A Feith GW. Acute renal failure following treatment with intravenously administered immunoglobulin. Ned Tijdschr Geneeeskd 2003;147:307-10.
15. Epstein JS, Zoon KC. Letter to health care providers-Important drug worning: Immune Globulin Intravenous (Human.. Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, 13 November 1998. Available at: www.fda.gov./cber/ltr/igiv111.398.htm.
16. Chako B, John GT, Balakrishnan N, Kirubakaran MG, Jacob CK. Osmotic nephropathy resulting from mlatose-based intravenous immunoglobulin therapy. Renal failure 2006;28:193-5.
17. Akhtar I, Bastani B. Acute renal failure and myocarditissassociated with intbavenous immunoglobulin therapy. Ann Intern Med 2003;139:E307-E8.
18. Levy JB, Pusey CD. Nephrotoxicity of intravenous immunoglobulin. Q J Med 2000;93:751-5.
19. Schifferli J, Leski M, Favre H, Imbach P, Nydegger U, Davies K. High dose intravenous IgG treatment and renal function. Lancet 1991;337:457-8.
20. Rigdon RH, Cardwell ES. Renal lesions following the intravenous injection of hypertonic solution of sucrose: a clinical and experimental study. Arch Intern Med 1942;69:670-90.
21. Cutler HH. Effect of sucrose on the kidney. Proc Staff Meet Mayo Clin 1939;14:318-20.
22. Dorman HR, Sondheimer JH, Cadnapaphornchai P. Mannitol-induced acute renal failure. Medicine 1990;69:153-9.
23. Ahsan N, Palmer BF, Wheeler D, Greenlee RG, Toto RD. Intravenous immunoglobulin-induced osmotic nephrosis. Arch Intern Med 1994;154:1985-7.
24. Markowitz GS, Perazella MA. Drug-induced renal failure: a focus on tubuloisterstitial disease. Clin Chim Acta 2005;351:31-47.
25. Orbach H, Tishler M, Shoenfeld Y. Intravenous immunoglobulin and the kidney; a two-edged sword. Semin Arthritis Rheum 2004;34:593-601.
26. Janigan DT, Santamaria A. A histochemical study of swelling and vacuolization of proximal tubular cells in sucrose nephrosis in the rat. Am J Pathol 1961;39:175-92.
27. Schwartz SL, Johnson CB. Pinocytosis as cause of sucrose nephrosis. Nephron 1971;8:246-54.
28. Hammak DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacology 2006;6:535-42.
29. Harden PN, Roberston S, Isles GC, Rodger RSC. Post-transplantation renal impairment and intravenous immunoglobulin. Nephrol Dial Transplant 1996;11:1896.
30. Samuel D. Liver transplantation and hepatitis B virus infection; the situation seems to be under control, but the virus is still there. J Hepatol 2001;34:943-5.
31. Lok ASP. Prevention of recurrent hepatitis B post-liver transplantation 2002;8( Suppl. 1.:s67-s73.
32. Pawarode A, Fine DM, Thuluvath. Independent risk factors and natural hystory of renal dysfunction in liver transplant recipients. Liver Transplant 2003;9:741-7.
33. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP et al. Liver transplantation in European patients with the hepatitis B surfaces antigen. N Engl J Med 1993;329:842-1847.
34. Marzano A, Gaia S, Ghisetti V, Carenzi S, Premoli A, Debernardi-Venon W et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 2005;11:402-9.
35. Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transpl 2004;10:S74-S85.
36. Shouval D, Samuel D. Hepatitis B immune globulin to prevent HBV graft reinfection following liver transplantation; a concise review. Hepatology 2000;32:1189-95.
37. Roche B, Feray C, Gigou M, Roque-Alfonso AM, Arulnader JL, Delvart V et al. HBV DNA persistence 10 years alter liver transplantation despite successful anti-HBs passive immunoprophylaxis. Hepatology 2003;38:86-95.
38. Samuel D, Bismuth A, Mathieu D, Arunalden JL, Reynes M, Benhamou JP et al. Passive immunoprophylaxis after liver transplantation in HbsAg positive patients. Lancet 1991;337:813-5.
39. Sawyer RG, McGory RW, Gaffey MJ. McCullough CC, Shephard BL, Houlgrave CW et al. Improved clinical outcome with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Ann Surg 1998;227:841-50.
40. O'Grady JG, Smith HM, Davies SE, Daniels HM, Donaldson PT, Tan KC et al. Hepatitis B reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatology 1992;14:104-11.
41. Lauchart W, Muller R, Pichlmayr R. Long-term immuno-prophylaxis of hepatitis B virus reinfection in recipients of human liver allografts. Transpl Proc 1987;19:4051-3.
42. Peters MG, Shouval D, Bonham A, Vierling JM, Lok AS. Posttransplantation future therapies. Sem Liver Dis 2000;20:19-24.
43. Di Paolo D, Tisone G, Piccolo P, Lenci I, Zazza S, Angelico M. Low-dose hepatitis B immunoglobulin given "on demand" in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver ransplantation. Transplantation 2004;77:1203-8.
44. Dickson RC, Terrault NA, Ishitani M, Reddy KR, Sheiner P, Luketic V et al. Protective antibody levels and dose requirements for IV 5% Nabi hepatitis B innune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease. Liver Transpl 2006;12:124-33.
45. Ferretti G, Merli M, Ginnani Corradini S, Callejon V, Tanzilli P, Masini A et al. Low-dose intramuscular Hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplanatation. Transpl Proc 2004;36:535-8.
46. Karademir S, Astarcioglu H, Akarsu M, Ozkardesler S, Ozzeybek D, Sayiner A et al. Prophylactic use of low-dose, on demand, intramuscular hepatitis B immunoglobulin and lamivudine after liver transplantation. Transpl Proc 2006;38:579-83.
47. Zheng S, Chef Y, Liang T, Lu A, Wang W, Shen Y. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B immunoglobulin prophylaxis. Liver Transpl 2006;12:253-8.
48. Marzano A, Salizzoni M, Be Bernardi-Venon W, SmedileA, Franchello A, Ciancio A et al. Prevention of hepatitis B recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001;34:903-10.
49. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immunoglobulin. Hepatology 1998;29:585-9.
50. Yao FY, Osorio RW, Roberts JP, Poordad FF, Briceno MN, Garcia-Kennedy R et al. Intramuscolar hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg 1999;5:491-6.
51. Yoshida FM, Erb SR, Partovi N, Scudamore CH, Chung SW, Frighetto L et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl Surg 1999;5:520-5.
52. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000;6:429-33.
53. Naoumov NV, Ross Lopes A, Barra P, Caccamo L, Iemmolo RM, de Man RA. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001;34:888-94.
54. Buti M, Mas A, Prieto M, Casafont F, Gonzalez A, Miras M et al. A randomized study comparing lamivdine monotherapy after a short course of hepatitis B immuneglobulin (HBIg. and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003;38:811-7.
55. Al-Hemsi B, McGory RW, Shepard B, Ishitani MB, Stevenson WC, McCollough C et al. Liver transplantation for hepatitis B cirrhosis: clinical sequela of passive immunization. Clin Transpl 1996;10:668-75.
56. Lowell JA, Burgess S, Shency S. Mercury poisoning associated with hepatitis B immunoglobulin. Lancet 1996;347:480 (letter..
57. Gonwa TA, Morris CA, Goldstein RM, Husberg BS, Klintmalm GB. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome: experience in 300 patients. Transplantation 1991;51:428-30.
58. Mihatsch MJ, Thiel G, Ryffel B. Histopathology of cyclosporine nephrotoxicity. Transpl Proc 1988;20 (Suppl 3.:759-71.
59. Mihatsch MJ, Helmchen U, Casanova P, Habib R, Larsen S, Magil A et al. Kidney biopsy findings in cyclosporine-treated patients with insulindependent diabetes mellitus. Klin Wochenschr 1991;69:354-9.
60. Gudat F, Mihatsch MJ, Ryffel B, Thiel G. Cyclosporine nephropathy. In: Tisher CC, ed. Renal pathology with clinical and functional correlations. Philadelphia: JB Lippincott Company; 199's. p 1641-82.
61. Bordmann PA, Andoh TF, Tu L, Bennett WM. Cyclosporine nephrotoxicity. Semin Nephrol 2003;23:465-76.
62. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporine- associated chronic nephropathy. N Engl J Med 1984;311:699-705.
63. Vieira JM Jr, Noronha IL, Malheiros DM, Burdmann EA. Cyclosporine-induced interstitial fibrosis and arteriolar TGFbeta expression with preserved renal blood Flow. Transplantation 1999;68:1746-53.
64. Whiting PH, Thompson AW, Blair JT, Simpson JG. Experimental cyclosperin A nephrotoxicity. Br J Exp Pathol 1982;63:88-94.
65. Burdmann EA, Andoh TF, Lindsley J, Russell J, Bennett WM, Porter G. Urinary enzymes as biomarkers of renal injury in experimental nephrotoxicity of immunosuppressive drugs. Renal Fail 1994;16:161-8.
66. Ernest S, Bello-Reuss E. P-glycoprotein functions and substrates: possible roles of MDR1 gene in the kidney. Kidney Int 1998;65( Suppl.:S11-S7.
67. Tsuruoka S, Sugimoto KI, Fujimura A, Imai M, Asano Y, Muto S. P-glycoprotein-mediated drug secretion in muse proximaltubule perfused in vitro. J Am Soc Nephrol 2001;12:177-81.
68. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993;268:6077-80.
69. Robinson LJ, Roberts WK, Ling TT, Lamming D, Sternberg SS, Roepe PD. Human MDR 1 protein overexpression delays the apoptotic cascade in Chinese hamster ovary fibroblasts. Biochemistry 1997;36:11169-78.
70. Johnstone RW, Fuefli AA, Smyth MJ. Multiple physiological functions for multidrug transporter p-glycoprotein? Trends Biochem Sci 2001;25:1-6.
71. Ernest S, Rajaraman S, Megyesi J, Bello Reuss EN. Expression of MDR1 (multidrug resistance, gene and its protein in normal human kidney. Nephron 1997;77:284-9.
72. Hauser IA, Koziolek M, Hopfer U, Thevenod F. Therapeutic concentrations of cyclosporine A, but not FK506, increase Pglycoprotein expression in endothelial and renal tubule cells. Kidney Int 1998;54:1139-49.
73. Melanie SJ, Volker N, Hogan SL, Thompson BD, Finn WF. Calcineurin inhibitor-induced nephrotoxicity and renal expression of p-glycoprotein. Pharmacotherapy 2005;25:779-89.
74. Schlitt HJ, Barkmann A, Boker KH, Schmidt HH, Emmanouilidis N, Rosenau J. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet 2001;357:587-91.
75. Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl 2003;9:1079-85.